Navigation Links
ThermoGenesis Presentation at Rodman & Renshaw Conference
Date:11/7/2008

RANCHO CORDOVA, Calif., Nov. 7 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products that process and store adult stem cells, announced today that it will be participating in the Rodman & Renshaw 10th Annual Healthcare Conference on Monday, November 10, 2008.

The Company's presentation by Dr. William Osgood, the Company's CEO, will begin at 2:50 p.m., Eastern Standard Time (11:50 am, Pacific Standard Time), and will be held at the New York Palace Hotel, located at 455 Madison Ave., New York, NY 10022.

Webcast

The presentation will be webcast LIVE and archived for 90 days, streaming video and PowerPoint slides. Access is available by logging on to the conference website http://www.wsw.com/webcast/rrshq14/kool or by going to the Company's website http://www.thermogenesis.com. It is recommended that interested parties register at least 15 minutes prior to the start of the presentation to ensure timely access.

About ThermoGenesis Corp.

ThermoGenesis Corp. (http://www.thermogenesis.com) is a leading supplier of innovative products and services that process and store adult stem cells for treatment of disease and injury.

ThermoGenesis Corp.

Web site: http://www.thermogenesis.com

Contact: Investor Relations

+1-916-858-5107, or

ir@thermogenesis.
'/>"/>

SOURCE ThermoGenesis Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal Year 2007 on September 12, 2007
2. ThermoGenesis Corp. Reports Fourth Quarter and Fiscal Year 2007 Results
3. ThermoGenesis Corp. to Present at 2007 Global Life Sciences Conference on Thursday, September 27, 2007
4. ThermoGenesis Corp. to Announce First Quarter Fiscal 2008 Results on November 8, 2007
5. ThermoGenesis Corp. to Announce Second Quarter Fiscal 2008 Results on February 6, 2008
6. ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year
7. ThermoGenesis Corp. Announces Voluntary Recall of Selected Lots of AXP Bag Sets
8. ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equine Health
9. ThermoGenesis Names Dr. Mahendra Rao to Board of Directors
10. ThermoGenesis Announces Receipt of CE Mark for MarrowXpress(TM)
11. ThermoGenesis Announces FDA Authorization to Market MarrowXpress(TM) (MXP(TM))
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... CAMBRIDGE, Mass. and REYKJAVIK, Iceland ... provides comprehensive capabilities for using the genome to create better ... publication of the largest studies of whole-genome data yet undertaken. ... Nature Genetics – are built around ... authored by a team of deCODE scientists led by ...
(Date:3/25/2015)... (PRWEB) March 25, 2015 Data ... Novel Mechanism of Action in Neuromuscular Diseases ... – Cytokinetics, Incorporated (Nasdaq: CYTK) announced the publication ... muscle troponin activator tirasemtiv in the journal Neurotherapeutics. ... IIa “Evidence of Effect” or hypothesis-generating clinical trial ...
(Date:3/25/2015)... the HAGUE, Netherlands , March 25, ... LES Stimulation therapy for chronic gastro-esophageal reflux disease (GERD) ... [ Surgery . 2015; 157(3):556-567 ], establishing ... therapy. The study included 25 patients ... years and taking prescribed daily proton pump inhibitor (PPI) ...
(Date:3/25/2015)... March 25, 2015  18 piglets born recently ... research by scientists in the College of Agriculture and ... a breakthrough in the field of genetic engineering. ... of Animal & Avian Sciences (ANSC) and Ki-Eun ... successfully produced genome-edited pigs using a recently developed, ...
Breaking Biology Technology:Landmark deCODE Studies Demonstrate the Power of Truly Big Genomics for Improving Medicine Worldwide 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6EndoStim LES Stimulation therapy demonstrates long term safety and efficacy results in treating reflux patients 2EndoStim LES Stimulation therapy demonstrates long term safety and efficacy results in treating reflux patients 3University of Maryland Researchers Successfully Produce Genome-edited Pigs Using Revolutionary Technology 2
... - Trent 1000 engines have been selected, - New environmental partnership ... ... burn, SOUTH NORWALK, Conn., March 3 ... has selected,Rolls-Royce Trent 1000 engines to power its Boeing 787-9 fleet of ...
... LELYSTAD, Netherlands, March 3, Genmab A/S (OTC: GNMSF) ... collaboration aimed at identifying fully,human monoclonal antibodies against ... difficult to address using,commonly available technologies but are ... can for example be due to the,fact that ...
... Inc.,(Nasdaq: VRML ), a high-value molecular diagnostics ... exclusive license agreement with Stanford,University to develop and ... risk of peripheral artery disease (PAD). Estimated to ... serious condition that often goes,undiagnosed. The disease can ...
Cached Biology Technology:Virgin Atlantic Selects Rolls-Royce Engines to Power Its 787 Fleet in a Deal Worth $2.6BN 2Virgin Atlantic Selects Rolls-Royce Engines to Power Its 787 Fleet in a Deal Worth $2.6BN 3Virgin Atlantic Selects Rolls-Royce Engines to Power Its 787 Fleet in a Deal Worth $2.6BN 4Genmab and Pepscan to Identify Human Antibodies Against Intractable Targets 2Genmab and Pepscan to Identify Human Antibodies Against Intractable Targets 3Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk 2Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk 3
(Date:3/10/2015)...  Continuing its 167-year history of offering the Best, ... The Eye Scanning Password Authenticator , a device that ... websites or sensitive data. Employing the same ... the device has a small camera that scans and ... converting them into an encrypted ID that cannot be ...
(Date:3/10/2015)... 10, 2015  NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing ... wallet has been named the "Number One Best ... Rethink Modern ( http://www.rethinkmodern.com/ ) is a ... home and lifestyle that have a unique function or ...
(Date:3/3/2015)... March 3, 2015 Cryoport, Inc. ... advanced cryogenic logistics solutions for the life ... cells, cell lines, clinical research organizations, vaccine ... announced the expansion of its relationship with ... ("Fred Hutch") Clinical Research Division with the ...
Breaking Biology News(10 mins):Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 4Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3
... Bacteria that generate significant amounts of electricity could be ... remote environments or to convert waste to electricity. Professor ... bacteria with large numbers of tiny projections called pili ... power in fuel cells than bacteria with a smooth ...
... British scientists have discovered two new genes associated ... The results, from the largest ever Alzheimer,s genome-wide association ... Nature Genetics . They are the first new genes ... Alzheimer,s disease since 1993. The Alzheimer,s Research Trust ...
... is available in French . A breakthrough ... and Denmark has uncovered a new gene that could lead ... a better understanding of how this widespread disease develops. ... diabetes, the new gene, called Insulin Receptor Substrate 1 (IRS1), doesn,t ...
Cached Biology News:Largest ever Alzheimer's genome study unveils dementia mysteries 2Largest ever Alzheimer's genome study unveils dementia mysteries 3Diabetes advance: Researchers find gene that causes resistance to insulin 2Diabetes advance: Researchers find gene that causes resistance to insulin 3
Rabbit polyclonal to ZFP200 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGKSFNHKTNLNKHER (Human) Entrez Gene ID: 7752 Swiss Protein ID: P98182...
Human Ig Lambda-chain, clone ICO-16, Monoclonal Antibody...
Rabbit polyclonal to Warfarin ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to KLH...
WNV Core Antibody...
Biology Products: